{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:56:44Z","timestamp":1772164604509,"version":"3.50.1"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/501100000391","name":"Association for International Cancer Research (AICR)","doi-asserted-by":"publisher","award":["11-0017"],"award-info":[{"award-number":["11-0017"]}],"id":[{"id":"10.13039\/501100000391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["1003597"],"award-info":[{"award-number":["1003597"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: The majority of gastric cancer patients are diagnosed with late-stage disease, for which distinct molecular subtypes have been identified that are potentially amenable to targeted therapies. However, there exists no molecular classification system with prognostic power for early-stage gastric cancer (EGC) because the molecular events promoting gastric cancer initiation remain ill-defined.<\/jats:p>\n                  <jats:p>Experimental Design: miRNA microarrays were performed on gastric tissue from the gp130F\/F preclinical EGC mouse model, prior to tumor initiation. Computation prediction algorithms were performed on multiple data sets and independent gastric cancer patient cohorts. Quantitative real-time PCR expression profiling was undertaken in gp130F\/F-based mouse strains and human gastric cancer cells genetically engineered for suppressed activation of the oncogenic latent transcription factor STAT3. Human gastric cancer cells with modulated expression of the miR-200 family member miR-429 were also assessed for their proliferative response.<\/jats:p>\n                  <jats:p>Results: Increased expression of miR-200 family members is associated with both tumor initiation in a STAT3-dependent manner in gp130F\/F mice and EGC (i.e., stage IA) in patient cohorts. Overexpression of miR-429 also elicited contrasting pro- and antiproliferative responses in human gastric cancer cells depending on their cellular histologic subtype. We also identified a miR-200 family\u2013regulated 15-gene signature that integrates multiple key current indicators of EGC, namely tumor invasion depth, differentiation, histology, and stage, and provides superior predictive power for overall survival compared with each EGC indicator alone.<\/jats:p>\n                  <jats:p>Conclusions: Collectively, our discovery of a STAT3-regulated, miR-200 family\u2013associated gene signature specific for EGC, with predictive power, provides a molecular rationale to classify and stratify EGC patients for endoscopic treatment. Clin Cancer Res; 24(6); 1459\u201372. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-17-2485","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T13:16:22Z","timestamp":1515762982000},"page":"1459-1472","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer"],"prefix":"10.1158","volume":"24","author":[{"given":"Liang","family":"Yu","sequence":"first","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"3Department of Periodontology, School of Dentistry, Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}]},{"given":"Hugh","family":"Gao","sequence":"additional","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."}]},{"given":"Jesse J.","family":"Balic","sequence":"additional","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."}]},{"given":"Anna","family":"Tsykin","sequence":"additional","affiliation":[{"name":"4Discipline of Medicine, University of Adelaide, Adelaide, South Australia."},{"name":"5School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia."},{"name":"6Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia."}]},{"given":"Tae-Su","family":"Han","sequence":"additional","affiliation":[{"name":"7Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan."}]},{"given":"You Dong","family":"Liu","sequence":"additional","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."},{"name":"8Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai, China."}]},{"given":"Catherine L.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."}]},{"given":"Ji Kun","family":"Li","sequence":"additional","affiliation":[{"name":"8Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai, China."}]},{"given":"Jie Qi","family":"Mao","sequence":"additional","affiliation":[{"name":"8Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai, China."}]},{"given":"Patrick","family":"Tan","sequence":"additional","affiliation":[{"name":"9Genome Institute of Singapore, Singapore."},{"name":"10Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore."},{"name":"11Cancer Science Institute of Singapore, National University of Singapore, Singapore."}]},{"given":"Masanobu","family":"Oshima","sequence":"additional","affiliation":[{"name":"7Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan."}]},{"given":"Gregory J.","family":"Goodall","sequence":"additional","affiliation":[{"name":"4Discipline of Medicine, University of Adelaide, Adelaide, South Australia."},{"name":"5School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia."},{"name":"6Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia."}]},{"given":"Brendan J.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia."},{"name":"2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia."}]}],"member":"1086","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"2022061019063208300_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jso.20018","article-title":"Application of minimally invasive treatment for early gastric cancer","volume":"85","author":"Hyung","year":"2004","journal-title":"J Surg Oncol"},{"key":"2022061019063208300_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd english edition","volume":"14","author":"Association","year":"2011","journal-title":"Gastric Cancer"},{"key":"2022061019063208300_bib3","first-page":"7","article-title":"Early gastric cancer: current advances of endoscopic diagnosis and treatment","volume":"2016","author":"Zhu","year":"2016","journal-title":"Gastroenterol Res Prac"},{"key":"2022061019063208300_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00464-015-4184-z","article-title":"Redefining early gastric cancer","volume":"30","author":"Barreto","year":"2016","journal-title":"Surg Endosc"},{"key":"2022061019063208300_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-3-319-41388-4_16","article-title":"The Japanese viewpoint on the histopathology of early gastric cancer","volume":"908","author":"Sekine","year":"2016","journal-title":"Adv Exp Biol"},{"key":"2022061019063208300_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"2022061019063208300_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"2022061019063208300_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022061019063208300_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/sj.bjc.6605608","article-title":"Circulating microRNAs in plasma of patients with gastric cancers","volume":"102","author":"Tsujiura","year":"2010","journal-title":"Br J Cancer"},{"key":"2022061019063208300_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1470-2045(09)70343-2","article-title":"Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis","volume":"11","author":"Ueda","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022061019063208300_bib11","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1038\/onc.2011.558","article-title":"Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells","volume":"31","author":"Kong","year":"2012","journal-title":"Oncogene"},{"key":"2022061019063208300_bib12","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1038\/onc.2010.352","article-title":"MicroRNA dysregulation in gastric cancer: a new player enters the game","volume":"29","author":"Wu","year":"2010","journal-title":"Oncogene"},{"key":"2022061019063208300_bib13","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1158\/1078-0432.CCR-13-1326","article-title":"miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression","volume":"19","author":"Tang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061019063208300_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-13-1844","article-title":"Integrated MicroRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family","volume":"20","author":"Song","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061019063208300_bib15","first-page":"1727","article-title":"STAT3 and STAT1 mediate IL-11\u2013dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice","volume":"118","author":"Ernst","year":"2008","journal-title":"J Clin Invest"},{"key":"2022061019063208300_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nm1282","article-title":"Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-\u03b2 signaling","volume":"11","author":"Jenkins","year":"2005","journal-title":"Nat Med"},{"key":"2022061019063208300_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccr.2012.08.010","article-title":"STAT3-Driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation","volume":"22","author":"Tye","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061019063208300_bib18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1074\/mcp.M600170-MCP200","article-title":"Identification of protein expression signatures associated with helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays","volume":"5","author":"Ellmark","year":"2006","journal-title":"Mol Cell Proteomics"},{"key":"2022061019063208300_bib19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.07.014","article-title":"Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway","volume":"131","author":"Oshima","year":"2006","journal-title":"Gastroenterology"},{"key":"2022061019063208300_bib20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1261\/rna.035055.112","article-title":"The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease","volume":"19","author":"Wu","year":"2013","journal-title":"RNA"},{"key":"2022061019063208300_bib21","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.15252\/embj.201488641","article-title":"Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion","volume":"33","author":"Bracken","year":"2014","journal-title":"EMBO J"},{"key":"2022061019063208300_bib22","doi-asserted-by":"crossref","first-page":"e05005","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"eLife"},{"key":"2022061019063208300_bib23","doi-asserted-by":"crossref","first-page":"e1000676","DOI":"10.1371\/journal.pgen.1000676","article-title":"Oncogenic pathway combinations predict clinical prognosis in gastric cancer","volume":"5","author":"Ooi","year":"2009","journal-title":"PLoS Genetics"},{"key":"2022061019063208300_bib24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061019063208300_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"2022061019063208300_bib26","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1038\/onc.2017.121","article-title":"Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer","volume":"36","author":"West","year":"2017","journal-title":"Oncogene"},{"key":"2022061019063208300_bib27","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1158\/0008-5472.CAN-08-1942","article-title":"A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition","volume":"68","author":"Bracken","year":"2008","journal-title":"Cancer Res"},{"key":"2022061019063208300_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2010.07.023","article-title":"STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer","volume":"39","author":"Iliopoulos","year":"2010","journal-title":"Mol Cell"},{"key":"2022061019063208300_bib29","first-page":"10","article-title":"Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer","author":"Itadani","year":"2009","journal-title":"BMC Genomics"},{"key":"2022061019063208300_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1440-1827.2000.01117.x","article-title":"Molecular characteristics of eight gastric cancer cell lines established in Japan","volume":"50","author":"Yokozaki","year":"2000","journal-title":"Path Int"},{"key":"2022061019063208300_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"2022061019063208300_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061019063208300_bib33","first-page":"1744","article-title":"Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth","volume":"52","author":"Shimakura","year":"1992","journal-title":"Cancer Res"},{"key":"2022061019063208300_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/den.12518","article-title":"Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer","volume":"28","author":"Ono","year":"2016","journal-title":"Dig Endosc"},{"key":"2022061019063208300_bib35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1189\/jlb.0410226","article-title":"More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer","volume":"88","author":"Putoczki","year":"2010","journal-title":"J Leukoc Biol"},{"key":"2022061019063208300_bib36","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/nm.2512","article-title":"miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response","volume":"17","author":"Mateescu","year":"2011","journal-title":"Nat Med"},{"key":"2022061019063208300_bib37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.2401","article-title":"Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization","volume":"17","author":"Korpal","year":"2011","journal-title":"Nat Med"},{"key":"2022061019063208300_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2015\/865816","article-title":"The regulatory role of microRNAs in EMT and cancer","volume":"2015","author":"Zaravinos","year":"2015","journal-title":"J Oncol"},{"key":"2022061019063208300_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2014.05.084","article-title":"MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes","volume":"450","author":"Lang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061019063208300_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2620-7","article-title":"Overexpression of the miR-141\/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K\/AKT signaling pathways by secreting VEGF-A","volume":"16","author":"Choi","year":"2016","journal-title":"BMC Cancer"},{"key":"2022061019063208300_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1593\/neo.121828","article-title":"Downregulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression","volume":"15","author":"Paterson","year":"2013","journal-title":"Neoplasia"},{"key":"2022061019063208300_bib42","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/0008-5472.CAN-15-0287","article-title":"Network-based approaches to understand the roles of miR-200 and other microRNAs in cancer","volume":"75","author":"Bracken","year":"2015","journal-title":"Cancer Res"},{"key":"2022061019063208300_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/PL00011720","article-title":"Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers","volume":"3","author":"Gotoda","year":"2000","journal-title":"Gastric Cancer"},{"key":"2022061019063208300_bib44","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3892\/ol.2015.3028","article-title":"Expression and clinical significance of the microRNA-200 family in gastric cancer","volume":"9","author":"Chang","year":"2015","journal-title":"Oncol Lett"},{"key":"2022061019063208300_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2211","article-title":"Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project","author":"Sohn","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2022061019063208300_bib46","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.celrep.2014.07.058","article-title":"The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression","volume":"8","author":"Han","year":"2014","journal-title":"Cell Rep"},{"key":"2022061019063208300_bib47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/24\/6\/1459\/2050018\/1459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/24\/6\/1459\/2050018\/1459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:10:30Z","timestamp":1654873830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/24\/6\/1459\/469\/Clinical-Utility-of-a-STAT3-Regulated-miRNA-200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,3,14]]},"published-print":{"date-parts":[[2018,3,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-2485","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.6524598","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6524598.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.22460808","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22460808.v1","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,14]]}}}